Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for spontaneous subarachnoid hemorrhage
ChiCTR2200062954Phase 4Not yet recruiting
- Sponsor
- 904th Hospital of the Joint Logistic Support Force
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing Pioglitazone with Placebo (2 arms). Primary endpoint: Modified Rankin Scale (mRS). Planned start Oct 2022; status: not yet recruiting.
02
Drugs
pioglitazone
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on ChiCTR2200062954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062954.